본문 바로가기
KERD
논문KCI 등재

Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence

Kirill Kosilov|Irina Kuzina|Sergay Loparev|Yuliya Gainullina|Liliya Kosilova|Alexandra Prokofyeva
대한배뇨장애요실금학회 (Korean Continence Society)|2018.10|International Neurourology Journal|제22권 제1호|pp. 41-50

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

Quality of lifeUrinary incontinenceMuscarinic antagonistsCognition disorders

초록

Purpose: The aim of this study was to investigate the safety and the effects of elevated doses of solifenacin and trospium on cognitive function and health-related quality of life (HRQoL) in elderly women receiving treatment for urinary incontinence. Methods: The study included 312 women aged 60–83 years (mean age, 69.4 years). All participants had scored at least 24 points on the Mini-Mental State Examination (MMSE) scale, and all of them had been diagnosed with urge urinary incontinence (UUI) or mixed urinary incontinence (MUI). The women were randomly assigned to 3 groups: group A, individuals who were simultaneously administered solifenacin at a high dosage of 20 mg per day and trospium at a high dosage of 60 mg per day; group B, persons taking solifenacin and trospium at the usual dosage of 10 and 30 mg per day, respectively; and group C, persons who received a placebo. Participants’ cognitive status was assessed by the MMSE, Controlled Oral Word Association Test, Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale III, Colour Trails Test, and California Verbal Learning Test scales. The HRQoL assessment was performed using the Medical Outcomes Study 36-Item Health Survey. Results: The cognitive function parameters did not differ at the start and end of the study across the groups (P>0.05). Additionally, the cognitive function parameters did not differ significantly within each group between the start and end of the study (P>0.05). The values of most HRQoL parameters regarding the functional state of the lower urinary tract (LUT) after the termination of treatment significantly improved in groups A and B (P<0.05). A significant correlation between cognitive status and HRQoL or LUT parameters was absent (r<0.3), while the correlations between HRQoL and LUT parameters were r=0.31–0.83, P<0.05. Conclusions: The use of elevated doses of solifenacin and trospium did not increase the risk of cognitive impairment in women with UUI and MUI. The combination of solifenacin and trospium at a double dosage may be recommended to elderly women with treatment-resistant symptoms of UUI and MUI. However, the safety of combining antimuscarinic drugs in women with an increased volume of residual urine requires further study.

Abstract

Purpose: The aim of this study was to investigate the safety and the effects of elevated doses of solifenacin and trospium on cognitive function and health-related quality of life (HRQoL) in elderly women receiving treatment for urinary incontinence. Methods: The study included 312 women aged 60–83 years (mean age, 69.4 years). All participants had scored at least 24 points on the Mini-Mental State Examination (MMSE) scale, and all of them had been diagnosed with urge urinary incontinence (UUI) or mixed urinary incontinence (MUI). The women were randomly assigned to 3 groups: group A, individuals who were simultaneously administered solifenacin at a high dosage of 20 mg per day and trospium at a high dosage of 60 mg per day; group B, persons taking solifenacin and trospium at the usual dosage of 10 and 30 mg per day, respectively; and group C, persons who received a placebo. Participants’ cognitive status was assessed by the MMSE, Controlled Oral Word Association Test, Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale III, Colour Trails Test, and California Verbal Learning Test scales. The HRQoL assessment was performed using the Medical Outcomes Study 36-Item Health Survey. Results: The cognitive function parameters did not differ at the start and end of the study across the groups (P>0.05). Additionally, the cognitive function parameters did not differ significantly within each group between the start and end of the study (P>0.05). The values of most HRQoL parameters regarding the functional state of the lower urinary tract (LUT) after the termination of treatment significantly improved in groups A and B (P<0.05). A significant correlation between cognitive status and HRQoL or LUT parameters was absent (r<0.3), while the correlations between HRQoL and LUT parameters were r=0.31–0.83, P<0.05. Conclusions: The use of elevated doses of solifenacin and trospium did not increase the risk of cognitive impairment in women with UUI and MUI. The combination of solifenacin and trospium at a double dosage may be recommended to elderly women with treatment-resistant symptoms of UUI and MUI. However, the safety of combining antimuscarinic drugs in women with an increased volume of residual urine requires further study.

참고문헌 (35)

  1. Abrams P, "Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence", Neurourol Urodyn, 29, pp.213~240 (2010)[DOI]
  2. Pfisterer MH, "The effect of age on lower urinary tract function: a study in women", J Am Geriatr Soc, 54, pp.405~412 (2006)[DOI]
  3. Coyne KS, "The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial", ethnic group and age: results from OAB-POLL, 2013, pp.32, 230~237
  4. Sensoy N, "Urinary incontinence in women: prevalence rates, risk factors and impact on quality of life", Pak J Med Sci, 29, pp.818~822 (2013)
  5. Coyne KS, "The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey", Value Health, 7, pp.455~463 (2004)[DOI]
  6. Kogan MI, "Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey", Curr Med Res Opin, 30, pp.2119~2130 (2014)[DOI]
  7. Shamliyan T, "Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review", Ann Intern Med, 156, pp.861~874 (2012)[DOI]
  8. Kosilov KV, "Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women", Urol Int, 93, pp.470~473 (2014)[DOI]
  9. Kosilov K, "A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron", Arch Gerontol Geriatr, 61, pp.212~216 (2015)[DOI]
  10. Erdem N, "Management of overactive bladder and urge urinary incontinence in the elderly patient", Am J Med, 119(3 Suppl 1), pp.29~36 (2006)[DOI]
  11. Gibson W, "Urinary incontinence in older people", Br J Hosp Med (Lond), 77, pp.27~32 (2016)[DOI]
  12. Cipullo LM, "Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview", Eur J Obstet Gynecol Reprod Biol, 174, pp.27~34 (2014)[DOI]
  13. Cardozo L, "Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)", BJU Int, 111, pp.804~810 (2013)[DOI]
  14. Salvatore S, "Cognitive dysfunction with tolterodine use", Am J Obstet Gynecol, 197, pp.e8~ (2007)
  15. Pagoria D, "Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients", Curr Urol Rep, 12, pp.351~357 (2011)[DOI]
  16. Wagg A, "Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study", Eur Urol, 64, pp.74~81 (2013)[DOI]
  17. Geller EJ, "Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial", Female Pelvic Med Reconstr Surg, 23, pp.118~123 (2017)[DOI]
  18. Kirill Kosilov, "Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women", International Neurourology Journal, 17(4), pp.191~196 (2013), 대한배뇨장애요실금학회
  19. Kosilov K, "Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect", Int J Urol Nurs, 9, pp.108~113 (2015)[DOI]
  20. Chancellor M, "Anticholinergics for overactive bladder therapy: central nervous system effects", CNS Neurosci Ther, 18, pp.167~174 (2012)[DOI]
  21. Wagg A, "Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder", Int J Clin Pract, 64, pp.1279~1286 (2010)[DOI]
  22. Kim A, "Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder", Low Urin Tract Symptoms, 9, pp.171~175 (2017)[DOI]
  23. Howland M, "Detecting change over time: a comparison of the SLUMS examination and the MMSE in older adults at risk for cognitive decline", CNS Neurosci Ther, 22, pp.413~419 (2016)[DOI]
  24. Demir O, "Prevalence and possible risk factors for urinary incontinence: a cohort study in the city of Izmir", Urol Int, 99, pp.84~90 (2017)[DOI]
  25. Kim SH, "Voiding diary might serve as a useful tool to understand differences between bladder pain syndrome", interstitial cystitis and overactive bladder, 2014, pp.21, 179~183
  26. Okada T, "The impact of lower urinary tract symptoms on generic health-related quality of life in male patients without co-morbidity", Nihon Hinyokika Gakkai Zasshi, 106, pp.172~177 (2015)
  27. Kirill Vladimirovich Kosilov, "Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms", International Neurourology Journal, 20(3), pp.240~249 (2016), 대한배뇨장애요실금학회
  28. Tugtepe H, "The effectiveness of transcutaneous electrical neural stimulation therapy in patients with urinary incontinence resistant to initial medical treatment or biofeedback", J Pediatr Urol, 11, pp.137.e1~137.e5 (2015)[DOI]
  29. Gomelsky A, "Treatment of mixed urinary incontinence", Cent European J Urol, 64, pp.120~126 (2011)[DOI]
  30. Cardozo L, "Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation", Int Urogynecol J, 23, pp.1581~1590 (2012)[DOI]
  31. Moga DC, "Bladder antimuscarinics and cognitive decline in elderly patients", Alzheimers Dement (N Y), 3, pp.139~148 (2017)
  32. Abrams P, "Clinical relevance of health-related quality of life outcomes with darifenacin", BJU Int, 102, pp.208~213 (2008)[DOI]
  33. Tang DH, "Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder", BJU Int, 113, pp.484~491 (2014)[DOI]
  34. Andersson KE, "The use of pharmacotherapy for male patients with urgency and stress incontinence", Curr Opin Urol, 24, pp.571~577 (2014)[DOI]
  35. Andersson KE, "The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction", Ther Adv Urol, 9, pp.11~27 (2017)[DOI]

관련 논문AI추천

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly WomenKirill Kosilov, Liliya Kosilova, Marina Ivanovskaya, Sergey Loparev대한배뇨장애요실금학회 · International Neurourology Journal2013 · 제17권 제4호Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms김연주, 배재현, 태범식대한배뇨장애요실금학회 · International Neurourology Journal2020 · 제24권 제3호Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder박재영, 배재현, 윤덕기, 장현경, 전병조, 태범식대한배뇨장애요실금학회 · International Neurourology Journal2024 · 제28권 제4호Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms김규식, 문홍상대한배뇨장애요실금학회 · International Neurourology Journal2016 · 제20권 제4호Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study최훈, 고우진, 김영호, 김준철, 배재현, 서주태, 오철영, 이광우, 이동환, 정성진, 최종보대한배뇨장애요실금학회 · International Neurourology Journal2018 · 제22권 제1호Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice나세리, 송미호, 전지연, 주명수, 한지연, 홍범식대한배뇨장애요실금학회 · International Neurourology Journal2014 · 제18권 제1호

이 간행물의 다른 논문 (29건)

Importance of Central Regulation for Lower Urinary Tract Functions조영삼pp. 1-1Animal Model of Interstitial Cystitis/Bladder Pain Syndrome권휘안pp. 1-2Central Regulation of Micturition and Its Association With Epilepsy권민정, 장현종, 조경옥pp. 2-8Animal Modelling of Interstitial Cystitis/Bladder Pain SyndromeKarl-Erik Andersson, Lori Birderpp. 3-9Synergistic Activities of Abdominal Muscles Are Required for Efficient Micturition in Anesthetized Female MiceAlvaro Munoz, Yolanda Cruz, Yingchun Zhang, Chuan Zhang, Timothy B. Boonepp. 9-19
원문 보기